Nancy Leung

Summary

Country: China

Publications

  1. doi Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues
    Nancy Leung
    Alice Ho Miu Ling Nethersole Hospital, Hong Kong, China The Chinese University of Hong Kong, Hong Kong, China
    Liver Int 31:85-9. 2011
  2. pmc Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues
    Nancy Leung
    Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Room 65, J6, 11 Chuen On Road, Taipo, NT, Hong Kong
    Hepatol Int 2:163-78. 2008
  3. pmc Chronic hepatitis B in Asian women of childbearing age
    Nancy Leung
    Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Chinese University of Hong Kong, Room 65, J6, 11 Chuen On Road, Tai Po, NT, Hong Kong SAR, China
    Hepatol Int 3:24-31. 2009
  4. doi Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir
    Nancy Leung
    Alice Ho Miu Ling Nethersole Hospital, Taipo, Hong Kong SAR, China
    Hepatology 49:72-9. 2009
  5. ncbi Viral hepatitis C in Hong Kong
    Nancy Leung
    Alice Ho Miu Ling Nethersole Hospital, 11 Chuen On Road, Taipo, NT, Hong Kong SAR, China
    Intervirology 49:23-7. 2006
  6. doi Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications
    Chee Kin Hui
    Department of Microbiology, The University of Hong Kong, Hong Kong SAR, China
    J Clin Gastroenterol 42:533-8. 2008
  7. ncbi Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase
    Chee Kin Hui
    Department of Medicine, University of Hong Kong, Hong Kong Special Administrative Region SAR, China
    Hepatology 46:395-401. 2007
  8. ncbi An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography results
    Tony S K Mok
    Department of Clinical Oncology, Prince of Wales Hospital, School of Public Health, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
    J Clin Oncol 23:8041-7. 2005
  9. ncbi Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B
    Chee Kin Hui
    Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China
    J Hepatol 47:191-202. 2007
  10. ncbi Chronic hepatitis B--treatment with nucleoside analogues
    Nancy Leung
    Alice Ho Miu Ling Nethersole Hospital and The Chinese University of Hong Kong, Hong Kong, SAR, China
    Med J Malaysia 60:22-7. 2005

Detail Information

Publications22

  1. doi Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues
    Nancy Leung
    Alice Ho Miu Ling Nethersole Hospital, Hong Kong, China The Chinese University of Hong Kong, Hong Kong, China
    Liver Int 31:85-9. 2011
    ..More importantly, there is a minimal risk of drug resistance during long-term therapy with these agents...
  2. pmc Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues
    Nancy Leung
    Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Room 65, J6, 11 Chuen On Road, Taipo, NT, Hong Kong
    Hepatol Int 2:163-78. 2008
    ..This paper critically reviews recent data published or presented since the APASL Consensus and Guideline Update of 2005. Clinical efficacy mostly in patients with raised serum alanine aminotransferase will be analyzed...
  3. pmc Chronic hepatitis B in Asian women of childbearing age
    Nancy Leung
    Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Chinese University of Hong Kong, Room 65, J6, 11 Chuen On Road, Tai Po, NT, Hong Kong SAR, China
    Hepatol Int 3:24-31. 2009
    ..This article reviews these issues and highlights areas in which their engagement with public health efforts serves to improve quality of life and society as a whole...
  4. doi Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir
    Nancy Leung
    Alice Ho Miu Ling Nethersole Hospital, Taipo, Hong Kong SAR, China
    Hepatology 49:72-9. 2009
    ..Both antivirals were well tolerated. Conclusion: Entecavir therapy resulted in earlier and superior reduction in HBV DNA compared with adefovir in nucleoside-naïve HBeAg-positive patients with CHB...
  5. ncbi Viral hepatitis C in Hong Kong
    Nancy Leung
    Alice Ho Miu Ling Nethersole Hospital, 11 Chuen On Road, Taipo, NT, Hong Kong SAR, China
    Intervirology 49:23-7. 2006
    ..Hepatitis C virus (HCV) infection can lead to serious liver disease. Its medico-socio-economic burden on society can be immense. This study investigates the epidemiology of HCV infection in Hong Kong...
  6. doi Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications
    Chee Kin Hui
    Department of Microbiology, The University of Hong Kong, Hong Kong SAR, China
    J Clin Gastroenterol 42:533-8. 2008
    ..Improvement in modified HAI after antiviral therapy has usually been defined as a 2-point reduction in modified HAI score...
  7. ncbi Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase
    Chee Kin Hui
    Department of Medicine, University of Hong Kong, Hong Kong Special Administrative Region SAR, China
    Hepatology 46:395-401. 2007
    ..40-0.20 U/year] versus 0.21 U/year [range 0-1.11 U/year], respectively, P = 0.04)...
  8. ncbi An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography results
    Tony S K Mok
    Department of Clinical Oncology, Prince of Wales Hospital, School of Public Health, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
    J Clin Oncol 23:8041-7. 2005
    ..To study the incidence and treatment outcomes of hepatocellular carcinoma (HCC) detected in an intensive surveillance program (ISP) of hepatitis B virus (HBV) carriers...
  9. ncbi Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B
    Chee Kin Hui
    Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China
    J Hepatol 47:191-202. 2007
    ..We studied the role of adiponectin in 2 chronic hepatitis B (CHB)-patient cohorts...
  10. ncbi Chronic hepatitis B--treatment with nucleoside analogues
    Nancy Leung
    Alice Ho Miu Ling Nethersole Hospital and The Chinese University of Hong Kong, Hong Kong, SAR, China
    Med J Malaysia 60:22-7. 2005
    ..Patient counseling is very important to decide on the choice among available therapeutic options. The assessment of the risks/benefits of each option should be carefully explained to individual patient...
  11. ncbi Lamivudine for chronic hepatitis B
    Nancy Leung
    Alice Ho Miu Ling Nethersole Hospital, The Chinese University of Hong Kong, Hong Kong SAR
    Expert Rev Anti Infect Ther 2:173-80. 2004
    ....
  12. ncbi Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy
    Chee Kin Hui
    Centre For The Study of Liver Diseases, The University of Hong Kong, Hong Kong SAR, China
    Gastroenterology 131:59-68. 2006
    ..De novo hepatitis B virus (HBV)-related hepatitis after chemotherapy results in high morbidity and mortality. We evaluate the clinical course of de novo HBV-related hepatitis after chemotherapy...
  13. ncbi Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients
    Chee Kin Hui
    Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region SAR, China
    Hepatology 46:690-8. 2007
    ..00 to -0.70 fibrosis units/year, versus median 0.51 fibrosis units/year, range 0 to +2.03 fibrosis units/year, P = 0.02)...
  14. pmc Comparison of real-time PCR assays for monitoring serum hepatitis B virus DNA levels during antiviral therapy
    Chee Kin Hui
    Department of Medicine, University of Hong Kong, Hong Kong, SAR, China
    J Clin Microbiol 44:2983-7. 2006
    ..The results of the RealART and Digene Hybrid assays were related (r = 0.94; P < 0.001) and diverged by 2 orders of magnitude. The RealART assay can be used to effectively monitor serum hepatitis B virus DNA levels...
  15. pmc Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study
    George K K Lau
    Clinical Trial Center, LKS Faculty of Medicine, The University of Hong Kong, Alice Ho Miu Ling Nethersole Hospital, Hong Kong SAR, China
    Korean J Hepatol 16:315-20. 2010
    ..In a previous pivotal phase III clinical study, 24 weeks treatment with clevudine 30 mg has been shown to profoundly suppress HBV replication and normalize serum alanine aminotransferase level...
  16. ncbi Viral breakthrough during lamivudine therapy for chronic hepatitis B
    Nancy Leung
    Alice Ho Miu Ling Hospital, Chinese University of Hong Kong, Hong Kong, SAR
    Intervirology 46:344-9. 2003
    ..Potent antiviral agents also lead to the decline of cccDNA in hepatocytes. Combination therapies may further improve efficacy and avoid viral breakthroughs...
  17. pmc Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B
    Lawrence Lai
    Department of Medicine, Caritas Medical Centre, Hong Kong SAR, China
    Int J Nanomedicine 1:255-62. 2006
    ..These recent data put pegylated interferon alpha-2a as the first choice of anti-HBV therapy, especially in young and motivated patients with chronic HBV infection...
  18. ncbi Mutational analysis of 65 Wilson disease patients in Hong Kong Chinese: identification of 17 novel mutations and its genetic heterogeneity
    Chloe Miu Mak
    Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China
    J Hum Genet 53:55-63. 2008
    ..The perfect linkage disequilibrium suggested that p.R778L and its private polymorphism p.L770L originated from a single ancestor. This East-Asian-specific mutation p.R778L/p.L770L is aged at least 5,500 years...
  19. ncbi HBV and liver cancer
    Nancy Leung
    Alice Ho Miu Ling Nethersole Hospital and The Chinese University of Hong Kong, Hong Kong, SAR, China
    Med J Malaysia 60:63-6. 2005
    ..However, they only constitute a minority proportion of treated patients. The mainstay of prevention should lie in prevention of HBV infection and early effective therapy of chronic hepatitis B infection...
  20. ncbi Clinical experience with lamivudine
    Nancy Leung
    Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China
    Semin Liver Dis 22:15-21. 2002
    ..This is accompanied by virological rebound and reversal of the initial therapeutic response, and sometimes by exacerbation of hepatitis. The need remains for effective, safe, and tolerable oral agents with durable activity against HBV...
  21. ncbi False-negative rate of abdominal sonography for detecting hepatocellular carcinoma in patients with hepatitis B and elevated serum alpha-fetoprotein levels
    Tony S K Mok
    Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China
    AJR Am J Roentgenol 183:453-8. 2004
    ....
  22. ncbi Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study
    Robert G Gish
    California Pacific Medical Center, San Francisco, CA, USA
    J Hepatol 43:60-6. 2005
    ..The aim of this study was to evaluate long term safety and antiviral activity of different doses of emtricitabine given once daily to patients chronically infected with hepatitis B...